aglepristone and Cat-Diseases

The aim of this study was to determine the therapeutic success of the medical treatment of pyometra with the antigestagen aglepristone and to document the recurrence rate in relation to the time interval after treatment with antigestagens in cats. Ten cats, 2-13 years of age and nulliparous were used in the study. The cats were treated with aglepristone at a dose of 10mg/kg body weight subcutaneously on days 1, 2, 7 and 14 (if not cured). In addition, trimethoprim/sulphadoxine was also administered at a dose of 15mg/kg body weight subcutaneously once a day for 7 days. Nine out of the 10 cats responded well to treatment. No recurrence was observed in a follow-up period of 2 years. No side effects were observed. The data suggest that aglepristone treatment is a promising approach for the medical treatment of pyometra in cats.

Topics: Animals; Anti-Bacterial Agents; Cat Diseases; Cats; Drug Therapy, Combination; Estrenes; Female; Injections, Subcutaneous; Male; Progestins; Pyometra; Sulfadoxine; Treatment Outcome; Trimethoprim

Fourteen female cats with fibroadenomatosis were treated with aglepristone, and the effectiveness of the treatment and its effect on selected haematological and blood chemistry parameters were studied. The cats were monitored for 12 months after the end of the treatment. Complete remission of the clinical signs was achieved on average 3.9 weeks after the treatment began; the success of the treatment confirmed the clinical diagnosis of fibroadenomatosis. During the course of the treatment the cats' haematological parameters returned to normal. In cats that had previously been treated with long-acting medroxyprogesterone acetate, treatment with aglepristone for five weeks was recommended. Cases of fibroadenomatosis reappearing after a few months should be regarded as new disease rather than a relapse. Six cats were subsequently mated and four gave birth to one or more litters; all the pregnancies proceeded normally with no clinically evident fibroadenomatosis. The other eight cats underwent ovariohysterectomy soon after the aglepristone treatment was completed.

Topics: Animals; Biomarkers; Blood Chemical Analysis; Cat Diseases; Cats; Estrenes; Female; Fertility; Fibroadenoma; Follow-Up Studies; Mammary Neoplasms, Animal; Receptors, Progesterone; Recurrence; Remission Induction; Treatment Outcome

Topics: Animals; Cat Diseases; Cats; Diagnosis, Differential; Estrenes; Fibroadenoma; Male; Mammary Glands, Animal; Mammary Neoplasms, Animal; Treatment Outcome; Turkey; Ultrasonography

Three cases of fibroepithelial hyperplasia (FEH) of the mammary gland in the cat are reported. A one year old female cat had a distinct enlargement of the middle mammary glands, one on each side, 5 days after the first estrus. One week later the cat was treated with medroxyprogesterone acetate (Depo-Promone). The affected glands, along with the remaining glands, increased further in size. A five year old female cat was treated with Proligeston (Covinan) for the suppression of estrus. Two weeks later fibroepithelial hyperplasia occurred in two glands, one with a well demarcated ulceration. A seven months old male cat was treated with delmadinon acetate (Tarden) because of urine spraying. Two months later he had enlargement of all mammary glands. All three cats were treated with the progesterone antagonist Aglépristone (Alizine). Within 5 to 11 weeks the mammary glands had regressed to normal.

Topics: Animals; Cat Diseases; Cats; Chlormadinone Acetate; Estrenes; Female; Hyperplasia; Male; Mammary Glands, Animal; Medroxyprogesterone Acetate; Progesterone; Progesterone Congeners; Treatment Outcome

Topics: Animals; Cat Diseases; Cats; Estrenes; Female; Fibroadenoma; Hormone Antagonists; Hyperplasia; Male; Mammary Glands, Animal; Mammary Neoplasms, Animal; Ovariectomy; Progesterone